Ally Bridge Group NY LLC Makes New Investment in Atyr PHARMA INC (NASDAQ:ATYR)

Ally Bridge Group NY LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 699,730 shares of the company's stock, valued at approximately $2,533,000. Atyr PHARMA accounts for 2.1% of Ally Bridge Group NY LLC's investment portfolio, making the stock its 22nd biggest holding. Ally Bridge Group NY LLC owned about 0.83% of Atyr PHARMA as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Atyr PHARMA by 467.8% in the fourth quarter. JPMorgan Chase & Co. now owns 178,532 shares of the company's stock valued at $646,000 after purchasing an additional 147,092 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Atyr PHARMA during the fourth quarter worth $144,000. Wells Fargo & Company MN bought a new position in Atyr PHARMA in the 4th quarter worth about $383,000. American Century Companies Inc. purchased a new stake in shares of Atyr PHARMA in the fourth quarter worth about $319,000. Finally, Victory Capital Management Inc. bought a new position in shares of Atyr PHARMA in the fourth quarter valued at approximately $37,000. Institutional investors own 61.72% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ATYR. Leerink Partners began coverage on Atyr PHARMA in a research report on Tuesday, February 18th. They set an "outperform" rating and a $16.00 target price for the company. HC Wainwright reiterated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a report on Friday, March 14th. Finally, Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a research report on Tuesday, February 18th. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $18.60.

Atyr PHARMA Trading Down 0.8 %

NASDAQ ATYR traded down $0.03 during trading hours on Wednesday, hitting $3.21. 677,403 shares of the company were exchanged, compared to its average volume of 904,733. The stock has a market cap of $284.79 million, a PE ratio of -3.41 and a beta of 0.79. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a 50-day moving average price of $3.27 and a 200 day moving average price of $3.40. Atyr PHARMA INC has a 52 week low of $1.42 and a 52 week high of $4.66.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. Analysts forecast that Atyr PHARMA INC will post -0.91 earnings per share for the current fiscal year.

Atyr PHARMA Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.